BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:‘Novel dual-action combination therapy enhances angiogenesis whi
 lst reducing tumour growth and spread’ - Professor Kairbaan Hodivala-Dil
 ke\, Professor of Angiogenesis\, Deputy Institute Director QMUL 
DTSTART:20150707T100000Z
DTEND:20150707T110000Z
UID:TALK59790@talks.cam.ac.uk
CONTACT:Mala Jayasundera
DESCRIPTION:Increasing chemotherapy delivery to tumors\, whilst enhancing 
 drug uptake and reducing side effects\, is a primary goal of cancer resear
 ch. In mouse and human cancer models in vivo\, we show that co-administrat
 ion of low dose Cilengitide and Verapamil\, increases tumor angiogenesis\,
  leakiness\, blood flow and Gemcitabine delivery. This approach reduces tu
 mor growth\, metastasis and minimizes side effects whilst extending surviv
 al. At a molecular level\, this strategy alters gemcitabine transporter an
 d metabolizing enzyme expression levels\, enhancing the potency of Gemcita
 bine within tumor cells in vivo and in vitro. Thus\, the dual action of lo
 w dose Cilengitide\, in vessels and tumor cells\, improves chemotherapy ef
 ficacy. Overall\, our data demonstrate that vascular promotion therapy is 
 a novel means to improve cancer treatment. 
LOCATION:Sackler Lecture Theatre (Level 7)\, Cambridge Institute for Medic
 al Research
END:VEVENT
END:VCALENDAR